OncoMed Pharmaceuticals Priced, Nasdaq: OMED.XX
Biotech developing new antibody therapeutics to be used in cancer treatments.
Industry: Health Care
First Day Return: +59.9%
OMED.XX
Biotech developing new antibody therapeutics to be used in cancer treatments.
| IPO Data | |
|---|---|
| IPO Date | 07/17/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $82 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Redwood City, CA, United States |
| Founded | 2004 |
| Employees at IPO | 83 |
| Website www.oncomed.com | |
IPO News for OncoMed Pharmaceuticals
OncoMed Pharmaceuticals (OMED.XX) Performance
